Biomaterial Database

[Case of malignant monocytic reticulosis; cutaneous aspects of malignant reticulosis; attempted synthesis; classification of reticuloses]. 1950

R VACHON, and P MOREL, and H BOURGEOIS

UI	MeSH Term	Description	Entries
D009000	Monocytes	Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.	Monocyte
D012157	Mononuclear Phagocyte System	Mononuclear cells with pronounced phagocytic ability that are distributed extensively in lymphoid and other organs. It includes MACROPHAGES and their precursors; PHAGOCYTES; KUPFFER CELLS; HISTIOCYTES; DENDRITIC CELLS; LANGERHANS CELLS; and MICROGLIA. The term mononuclear phagocyte system has replaced the former reticuloendothelial system, which also included less active phagocytic cells such as fibroblasts and endothelial cells. (From Illustrated Dictionary of Immunology, 2d ed.)	Reticuloendothelial System,Phagocyte System, Mononuclear,System, Mononuclear Phagocyte,System, Reticuloendothelial
D000279	Administration, Cutaneous	The application of suitable drug dosage forms to the skin for either local or systemic effects.	Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D054747	Histiocytic Sarcoma	Malignant neoplasms composed of MACROPHAGES or DENDRITIC CELLS. Most histiocytic sarcomas present as localized tumor masses without a leukemic phase. Though the biological behavior of these neoplasms resemble lymphomas, their cell lineage is histiocytic not lymphoid.	Histiocytosis, Malignant,Malignant Histiocytosis,True Histiocytic Lymphoma,True Malignant Histiocytosis,Histiocytic Lymphoma, True,Histiocytic Lymphomas, True,Histiocytic Sarcomas,Histiocytoses, Malignant,Histiocytoses, True Malignant,Histiocytosis, True Malignant,Lymphoma, True Histiocytic,Lymphomas, True Histiocytic,Malignant Histiocytoses,Malignant Histiocytoses, True,Malignant Histiocytosis, True,Sarcoma, Histiocytic,Sarcomas, Histiocytic,True Histiocytic Lymphomas,True Malignant Histiocytoses
D020135	Peptide Nucleic Acids	DNA analogs containing neutral amide backbone linkages composed of aminoethyl glycine units instead of the usual phosphodiester linkage of deoxyribose groups. Peptide nucleic acids have high biological stability and higher affinity for complementary DNA or RNA sequences than analogous DNA oligomers.	Peptide Nucleic Acid,Acid, Peptide Nucleic,Acids, Peptide Nucleic,Nucleic Acid, Peptide,Nucleic Acids, Peptide